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Abstract
Background: The epigenetic machinery is frequently altered in acute myeloid leukemia. Focusing on cytogenetically
normal (CN) AML, we previously described an abnormal H3K27me3 enrichment covering 70 kb on the HIST1 cluster
(6.p22) in CN-AML patient blasts. Here, we further investigate the molecular, functional, and prognosis significance of
this epigenetic alteration named H3K27me3 HIST1 in NPM1-mutated (NPM1mut) CN-AML.
Results: We found that three quarter of the NPM1mut CN-AML patients were H3K27me3 HIST1high. H3K27me3
HIST1high group of patients was associated with a favorable outcome independently of known molecular risk factors. In
gene expression profiling, the H3K27me3 HIST1high mark was associated with lower expression of the histone genes
HIST1H1D, HIST1H2BG, HIST1H2AE, and HIST1H3F and an upregulation of genes involved in myelomonocytic
differentiation. Mass spectrometry analyses confirmed that the linker histone protein H1d, but not the other histone H1
subtypes, was downregulated in the H3K27me3 HIST1high group of patients. H1d knockdown primed ATRA-mediated
differentiation of OCI-AML3 and U937 AML cell lines, as assessed on CD11b/CD11c markers, morphological and gene
expression analyses.
Conclusions: Our data suggest that NPM1mut AML prognosis depends on the epigenetic silencing of the HIST1 cluster
and that, among the H3K27me3 silenced histone genes, HIST1H1D plays a role in AML blast differentiation.
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Background
Acute myeloid leukemias (AMLs) are a heterogeneous
group of severe hematological malignancies that arise
through the acquisition of oncogenic mutations by
hematopoietic progenitor cells. Patient prognosis mainly
relies on the given treatment, the outcome of which de-
pends on cytogenetics and molecular alterations. Cytoge-
netically normal (CN) AML patients are usually assigned
to an intermediate prognosis group that can be further
subdivided through the detection of mutations in a
growing number of genes [1]. Mutations in the nucleo-
phosmin 1 (NPM1) gene are the commonest molecular
lesions occurring in ≥ 50% of cases with cytogenetically
normal acute myeloid leukemia (CN-AML). NPM1
mutations result in the generation of a nuclear export
signal causing the delocalization of the protein from the
nucleoli to the cytoplasm [2]. Analyses of large numbers
of patients have shown that NPM1 mutations are
associated with a relatively favorable prognosis, which can
be mitigated by internal tandem duplications (ITD) of the
tyrosine kinase receptor Fms-like tyrosine kinase 3 (FLT3)
and mutations in DNA-methyl transferase 3A (DNMT3A).
Indeed, in NPM1mut CN-AML, FLT3ITD mutation, and/
or mutation in DNMT3A predict an increased risk of
relapse and poorer outcome [3], [4]. Recent reports shed
light on the importance of epigenetic deregulations that
affect the epigenome and gene transcription in AML
pathogenesis [5]. These deregulations are the
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consequence of numerous alterations found in genes en-
coding multiple classes of epigenetic proteins as DNA
methylation and histone modification enzymes [6].
In addition to these mutations, recent reports under-
lined the importance of histone genes themselves in can-
cer onset. For example, the major histone cluster 1
(HIST1), encoding the vast majority of the redundant core
and linker histones [7], has been found partially deleted in
ALL [8] and deregulation of its expression is associated
with breast cancer invasiveness [9]. Moreover, we previ-
ously described a new alteration that affects the HIST1
cluster in AML. This alteration consists in a marked his-
tone H3 lysine 27 tri-methylation (H3K27me3) enrich-
ment encompassing 70 kb of the HIST1 cluster, affecting
histone genes and associates with the NPM1 mutation
and a better leukemia-free survival [10]. In this study, we
reported the clinical importance of this newly identified
epigenetic alteration, called the H3K27me3 HIST1 mark,
in relation to other known mutations and its functional
consequences on the biology of CN-AML leukemic cells.
We revealed that H3K27me3 HIST1 status and histone
mRNA and protein levels define clinically and biologically
different subgroups of NPM1mut CN-AML suggesting
their importance in AML pathogenesis.
Results
H3K27me3 level on HIST1 locus is associated with better
survival
To characterize the H3K27me3 HIST1 mark, we performed
H3K27me3 ChIP-qPCR on samples obtained from 46 de
novo CN-AML patients included in GOELAMS multicenter
clinical trials LAM2006IR (NCT00860639) or LAM2007SA
(NCT00590837). H3K27me3 level was determined at five
HIST1 genomic locations that are representative of the
H3K27me3 HIST1 signature, as described previously [10].
Heatmap showing H3K27me3 HIST1 gene enrichment con-
firmed the variation of H3K27me3 HIST1 level among CN-
AML patients (Fig. 1a). The average of the five normalized
H3K27me3 HIST1 values was calculated and this index
showed a clear segregation of the H3K27me3 HIST1low and
H3K27me3 HIST1high patients. With a cut-off value at 15,
approximately 55% of CN-AML samples displayed an
H3K27me3 HIST1 enrichment mark (Fig. 1b).
There was no association of H3K27me3 HIST1 status with
age, gender, FLT3ITD, DNMT3A, IDH1, or CCAAT/enhan-
cer-binding protein alpha (CEBPA) mutations (Fig. 1a and
Additional file 1: Table S1). However, we noted that 25/33
(75.7%) of the NPM1mut samples were also H3K27me3
HIST1high (Fig. 1a and Additional file 1: Table S1) confirming
our first observation [10]. In addition, we observed a signifi-
cant association between H3K27me3 HIST1high and the
presence of IDH2R140 mutation (36% vs. 4.7%, P= .01)
(Fig. 1a and Additional file 1: Table S1).
H3K27me3 HIST1high patients had a better overall sur-
vival (OS) and event-free survival (EFS) than H3K27me3
HIST1low patients, with a median OS of 50.9 months ver-
sus 14.6 months (HR, 2.5 [1.5–5.5]; P = .02) and a median
EFS of 37 months versus 9 months (HR, 2.7 [1.3–5.8];
P = .008) (Fig. 1c). The survival gain was independent in
multivariate analyses taking age and NPM1wt/FLT3ITD
status into account (Additional file 1: Table S2). These ob-
servations confirmed in an independent cohort the previ-
ously reported association of H3K27me3 HIST1high with a
better prognosis [10].
H3K27me3 level on HIST1 locus is an independent
biomarker predicting survival of NPM1mut CN-AML
NPM1-mutated AMLs represent a distinct clinical and bio-
logical entity in the World Health Organization (WHO) clas-
sification, commonly associated with a better prognosis [3].
We used the biological material obtained from 25 NPM1mut
samples previously analyzed [10], and 78 samples either pro-
vided by the GOELAMSTHEQUE (n= 33), or the IPC/
CRCM tumor bank (n= 45) (Fig. 2a). H3K27me3 status of
the 78 new samples was analyzed (Additional file 2: Figure
S1) and revealed that 75% of NPM1mut CN-AMLs were
H3K27me3 HIST1high. The NPM1mut H3K27me3 HIST1high
subgroup of patients was not enriched with DNMT3A or
FLT3ITD mutations, the most frequently NPM1mut co-
occurring alterations [11] (Table 1 and Additional file 2: Fig-
ure S1), but IDH2R140 was significantly overrepresented in
this subgroup in comparison with the NPM1mut
H3K27me3 HIST1low group (27.6% vs. 7.6%, P= .05). Inter-
estingly, H3K27me3 HIST1high leukemic cells had a signifi-
cantly lower CD34 expression than their H3K27me3
HIST1low counterparts (CD34 mean expression, 10.3% vs.
35%, P= 0.005) (Table 1). To further explore a potential as-
sociation between CD34 expression and the presence of
H3K27me3 HIST1 mark, we selected four patient samples
(two in each H3K27me3 HIST1 group), containing both
CD34low and CD34high blast populations. We next ana-
lyzed the H3K27me3 HIST1 level in CD34low and
CD34high fluorescence-activated cell sorted (FACS) blasts.
As shown in Fig. 2b and Additional file 2: Figure S2,
H3K27me3 HIST1 status (high or low), in both CD34low and
CD34high blast fractions, was similar to the bulk population,
indicating that H3K27me3 HIST1high occurs independently
of CD34 level of expression.
Next, we analyzed the prognosis impact of the H3K27me3
HIST1 alteration. NPM1mut H3K27me3 HIST1high patients
had a better OS and EFS than NPM1mut H3K27me3 HIS-
T1low patients (median OS, 38.3 vs. 15.7 months; HR, 2
[range, 1.0–3.0]; P= .03; median EFS, 20.9 vs. 10.6 months;
HR, 2.7 [range, 1.3–5.7]; P= .01) (Fig. 2c). In multivariate
analysis, taking age and FLT3ITD/DNMT3Amut into ac-
count, H3K27me3 HIST1high remained significantly associ-
ated with a favorable EFS suggesting that the prognostic
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significance of the H3K27me3 HIST1 signature is independ-
ent of other known molecular alterations (Table 2).
Finally, we studied the impact of H3K27me3 HIST1 mark
in the NPM1mut/FLT3wt subgroup, which is classically as-
sociated with a favorable prognosis [12]. H3K27me3
HIST1high patients (n= 36) displayed better OS and EFS than
H3K27me HIST1low patients (n= 17), (median OS,
111.6 months vs. 23.2 months; P= .03; median EFS,
44.1 months vs. 13.9 months; P= .01, for H3K27me3
HIST1high and H3K27me3 HIST1low, respectively) (Fig. 2d).
Our results suggest that H3K27me3 HIST1 status is an
independent epigenetic marker that identifies patients
with a poor outcome within the NPM1/FLT3wt group of
patients.
Histone mRNA expression is anti-correlated to H3K27me3
HIST1 level and predicts NPM1mut CN-AML patient
outcome
To analyze the anti-correlation of histone mRNA level
and the presence of the repressive H3K27me3 mark, we
selected three histone genes; HIST1H1D, HIST1H2BG
and HIST1H2BH, spread over the H3K27me3 HIST1
islet and associated with clinical outcome in public data
(see below), and measured their mRNA levels. Expres-
sion of these three genes was lower in H3K27me3
HIST1high patients (n = 34) than in H3K27me3 HIST1low
patients (n = 13) (Fig. 3a).
We next asked whether expression of these genes, as a
consequence of H3K27me3 mark, was associated with
patient survival. Given the small size of our cohort, we
analyzed HIST1 gene expression in two published co-
horts with publicly accessible clinical and mRNA expres-
sion data: TCGA [13] and Metzeler [14]. NPM1mut CN-
AML patients, within these two cohorts, were identified
by using a published gene expression signature that pre-
dicts the NPM1 mutational status [15] (see Add-
itional file 3: Supplemental methods). Association of
histone expression with survival was first tested for each
of the 11 histone genes covered by the H3K27me3
HIST1 mark. This highlighted three histone genes,
HIST1H1D, HIST1H2BG, and HIST1H2BH, for which
a high level of expression was associated with a poor
outcome (P = .004, .015 and .044 respectively, Fig. 3b).
Then, we tested this 3-HIST1-mRNA signature in
univariate analysis; 3-HIST1-mRNAlow patients had a
favorable OS with a median OS of 17.7 months ver-
sus 9.6 months (HR = 1.66, range, 1.13–2.42, P = .009)
(Fig. 3c). Multivariate analyses showed that the 3-HIST1-
mRNAlow status was associated with a better prognosis
(HR = 1.60, range 1.60–2.31, P = .01), independently of
Fig. 1 Analysis of H3K27me3 HIST1 level in CN-AML patients. a Heatmap of normalized H3K27me3 enrichment value obtained by H3K27me3
ChIP-qPCR on the indicated HIST1 genes. Enrichment was calculated as the percentage of bound/input and double normalized with HOXD4 and
GAPDH. Each column represents a patient sample (n = 46) sorted by unsupervised hierarchical clustering. The separation between H3K27me3
HIST1low and H3K27me3 HIST1high groups is indicated by a dotted lane. Yellow square: mutation for the indicated gene. b Bimodal distribution of
the patients according to H3K27me3 HIST1 mean level, obtained from the H3K27me3 enrichment values of the 5 HIST1 regions analyzed. In blue,
patients with an H3K27me3 HIST1 mean value below 15 (H3K27me3 HIST1low, n = 21), in red, patients with a mean value above 15 (H3K27me3
HIST1high, n = 25). c OS and EFS in CN-AML patients according to H3K27me3 HIST1low and H3K27me3 HIST1high status
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Fig. 2 (See legend on next page.)
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other prognosis markers including age, FAB classification
and FLT3 status (Additional file 1: Table S3).
These results show that H3K27me3 HIST1high is asso-
ciated with a lower expression of histone genes, and that
3-HIST1-mRNAlow signature defines a NPM1mut AML
patient group with a better outcome.
Gene expression profiling associated with H3K27me3
HIST1high identifies a “mature like” phenotype
We next characterized the gene expression profile (GEP)
of H3K27me3 HIST1high samples (n = 16) in comparison
to H3K27me3 HIST1low samples (n = 11) from the IPC co-
hort (see Additional File 1: Table S4 for patient clinical
characteristics). Eighty-one genes were differentially
expressed (p < .05, fold-change > 1.5) between the two
groups, 58 being up- and 23 being downregulated in the
H3K27me HIST1high group (Fig. 4a and Additional file 4:
Table S5). Analysis of enhancer of zeste homolog 2
(EZH2) and suppressor of zeste 12 (SUZ12) expres-
sion revealed that the two groups, H3K27me3
HIST1high and H3K27me3 HIST1low, equally
expressed PRC2 components (Fig. 4b). GSEA
Table 1 Clinical and molecular characteristics according to H3K27me3 HIST1 level in the NPM1mut AML cohort
Characteristics All patients (n = 103) H3K27me3 HIST1low (n = 28) H3K27me3 HIST1high (n = 75) P
Age, years 0.42
Median 61 62 60
Range 22–76 37–76 22–76
Sex, % 1.0
Male 43 42.8 44
WBC, × 10e9/L 67 87.9 55.6 0.57
Median 67 87.9 55.6
Range 10–352 10–352 11–230
Complete response, % 94 88.4 96.0 0.18
Allo-HSCT in 1st CR, % 23 32.1 20.0 0.2
FAB classification,% 1.0
0–2 51.8 50.0 52.6
4–5 48.2 50.0 47.4
CD34 expressiona 0.005
Mean 15.3 35.0 10.3
Range 0–99 12–99 0–93
Molecular alterations, %
FLT3ITD 47.0 37.0 50.6 0.36
DNMT3Ab 50.5 57.6 43.1 0.25
FLT3ITD/DNMT3Ab 23.1 23.1 23.1 1.0
IDH2 (R140)b 21.9 7.6 27.6 0.05
IDH1 (R132)b 12.1 15.3 10.7 0.72
CEBPAb 5.4 7.6 4.6 0.62
ASXL1b 3.2 3.8 3.1 1.0
Allo HSCT allogenic stem-cell transplantation, CR complete response, WBC white blood cell
aN = 72
bN = 91
(See figure on previous page.)
Fig. 2 Analysis of H3K27me3 HIST1 level in CN-AML patients with NPM1 mutation. a Consort diagram showing number and overlap of NPM1mut
AML samples analyzed in the different experiments. b Analysis of H3K27me3 HIST1 status in CD34low and CD34high blast populations. The left
panel presents an H3K27me3 HIST1high patient and the right panel an H3K27me3 HIST1low patient. For each panel are shown: the gating strategy
for separating blast cells according CD34 expression level (upper left), the H3K27me3 HIST1 status on the bulk population (upper right), on
CD34low blast population (lower left) and on CD34high blast population (lower right). c OS and EFS in NPM1mut CN-AML patients according to
H3K27me3 HIST1 status (n = 103). d OS and EFS in NPM1mut/FLT3wt CN-AML patients according to H3K27me3 HIST1 status (n = 53). Statistical
significance was estimated using the log-rank test
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identified, in H3K27me3 HIST1high patients, genes
associated with myelomonocytic differentiation such
as immune or inflammatory responses (Fig. 4c and
Additional file 4: Table S5). Downregulated genes in
these patients belong to cell cycle and chromatin
regulation categories, including histone genes from
the HIST1 cluster (Fig. 4c and Additional file 4:
Table S5). Using qPCR, we confirmed higher expres-
sion of three genes involved, in mature granulocyte
functions, CYBB, FCN1, and CLEC4A [16], [17], [18]
in H3K27me3 HIST1high patients (Fig. 4d).
H3K27me3 level at the promoter of these genes was
identical between H3K27me3 HIST1low and
H3K27me3 HIST1high patients (Additional file 2: Fig-
ure S3) suggesting that the variation of expression
was indirectly affected by H3K27me3 HIST1high.
To further validate the relation between low mRNA
level of HIST1 genes and the expression of granulocytic
markers, we tested mRNA expression of myelomonocy-
tic maturation genes (CYBB, FCN1, CLEC4, and
ITGAM) in the TCGA and Metzeler cohorts of patients
stratified with the previously defined 3-HIST1-mRNA
signature. The 3-HIST1-mRNAlow patient group overex-
pressed the differentiation genes in comparison to the 3-
HIST1-mRNAhigh one (Fig. 4e), thus corroborating our
previous observation (Fig. 4d). Reciprocally, genes such
as SOCS2, CDK6, LAPTM4B, and NGFRAP1, which
were described as associated with a leukemic stem cell
signature [19], were less expressed in the 3-HIST1-
mRNAlow patient group (Fig. 4f).
Taken together, these results suggest that HIST1
mRNA downregulation by the H3K27me3 HIST1high
mark is associated with a more differentiated phenotype
related to a committed state of leukemic cells.
Table 2 Multivariate analyses for H3K27me3 HIST1 status
Event-free survival
Multivariate analysis
Variables HR 95% CI P
H3K27me3 HIST1high 1.76 1.04–2.99 0.036
Age > 60 years 0.60 0.36–0.99 0.044
FLT3ITD/DNMT3 mut 0.48 0.27–0.83 0.009
Fig. 3 Gene expression from the HIST1 cluster impacts on survival in NPM1mut CN-AML. a mRNA analyses of HIST1 genes in the IPC cohort of
NPM1mut CN-AML patients. HIST1H1D (n = 46), HIST1H2BH (n = 45), and HIST1H2BG (n = 47) mRNA levels were determined by Taqman, according
to H3K27me3 HIST1 status. Gene expression was normalized on the average of two housekeeping genes (PGK1 and PPIA). Statistical significance
was estimated using Mann Whitney test * p < 0.05; **p < 0.005 ***p < 0.0001. b Influence of histone gene expression on OS by univariate analysis.
Only histone genes covered by the H3K27me3 HIST1 mark described in [10] were analyzed. c Survival analyzed according to the expression of
HIST1H1D, HIST1H2BG, and HIST1H2BH mRNA on independent cohorts of patients (TGCA and Metzeler). Patients were split into two groups
according to the expression of HIST1H1D, HIST1H2BH and HIST1H2BG genes using a Cox regression prognosis model. Statistical significance was
estimated using the log-rank test
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The histone linker H1-3 is poorly expressed in H3K27me3
HIST1high CN-AML patients
To study the role of histones on AML clinical and bio-
logical features, we looked at the effect of H3K27me3
HIST1 epigenetic silencing on histone protein level.
First, we looked at the proportions of total histones and
of each histone subtype (Additional file 2: Figure S4) in
chromatin-bound fractions extracted from a series of 12
patient samples (six in each group) using intensity-based
absolute quantification (iBAQ) approach. Normalized
quantities of total linker histone H1 and core histones
H2A, H2B, H3, and H4 were similar in both H3K27me3
HIST1high and H3K27me3 HIST1low patients (Additional
file 2: Figure S5), suggesting that H3K27me3 HIST1high
status did not globally modify histone protein abun-
dance. Then, we decided to analyze specifically the his-
tone linker H1-3, encoded by HIST1H1D, because its
mRNA level is affected by H3K27me3 HIST1 status
(Fig. 3a) and it is the leading gene for the mRNA signa-
ture (Fig. 3b). In addition, contrary to other histone
subtypes (i.e., H2A, H2B, H3, and H4), H1 histone
subtypes are heterogeneous in amino acid compos-
ition [20], which probably reflects a subtype-specific
function. Indeed, when looking at the H1 subtype
abundance, we observed that the H1-3 subtype was
decreased in the H3K27me3 HIST1high group (nor-
malized iBAQ value (Log2) = 6.09 vs 4.74; P = .04),
whereas the other H1 subtypes, H1-5, H1-2, H1-4,
H1-F0, and H1-FX, were unaffected (Fig. 5a). These
results are consistent with the specific HIST1H1D
mRNA expression decrease observed in AML samples
harboring the H3K27me3 HIST1 mark. We confirmed
the lower expression of H1-3 observed in H3K27me3
HIST1high group in comparison to H3K27me3
Fig. 4 H3K27me3 HIST1high is associated with a myelomonocytic Gene Expression Profile. a Volcano plot displaying differentially expressed genes
between H3K27me3 HIST1high (n = 16) and H3K27me3 HIST1low patients (n = 11). The blue dots represent the histone genes covered by the
H3K27me3 mark. b EZH2 and SUZ12 levels of expression obtained from our micro array data were analyzed in H3K27me3 HIST1low (n = 11) and
H3K27me3 HIST1high (n = 16) patients. c GSEA (gene set enrichment analysis) of H3K27me3 HIST1high samples. d Expression of three genes
associated with granulocytic functions according to H3K27me3 HIST1 status. CYBB (cytochrome B-245 beta chain); FCN1 (Ficolin 1); CLEC4A (C-type
lectin domain family 4 member A). Data are represented in relative expression to HPRT. e–f Patients from TGCA and GSE 61804 cohorts were
separated according to the 3-HIST1 mRNA signature in mRNAlow (n = 114) and mRNAhigh (n = 79) patients. e Myelomonocytic CYBB, FCN1, CLEC4A,
ITGAM (integrin subunit alpha M) and f leukemic stem cell SOCS2 (suppressor of cytokine signaling 2), CDK6 (cyclin dependent kinase 6), LAPTM4B
(lysosome-associated protein transmembrane-4β), and NGFRAP1 (nerve growth factor receptor-associated protein 1) gene expression was
analyzed. Statistical significance was estimated using Mann Whitney test * p < 0.05; **p < 0.005 ***p < 0.0001. NS non-significant
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HIST1low group of patients by Western blot using pan
H1 and specific H1-3 antibodies (Fig. 5b).
In conclusion, as a consequence of the presence of an
H3K27me3 islet, NPM1mut CN-AML H3K27me3
HIST1high patients express low level of H1-3.
H1-3 knockdown confers a more mature phenotype in
AML cell lines
We hypothesized that the better prognosis of H1-3 low
AML may be related to a gain of differentiation and a
loss of stem cell features of the AML blasts. Thus, we
tested the consequences of H1-3 knockdown (KD) on
differentiation potential of the NPM1-mutated OCI-
AML3 cell line, which also harbor the DNMT3AR882C
mutation [21]. Efficiency and specificity of our KD were
assessed by testing mRNA levels of the different H1 sub-
types (Fig. 6a and Additional file 2: Figure S6a and S6b)
and by measuring H1-3 protein level, after H1-3 KD in-
duction (Fig. 6b and Additional file 2: Figure S6c and
S6d). Consequences of H1-3 KD on differentiation were
evaluated upon all-trans retinoic acid (ATRA)-treatment.
Albeit no increase in CD11b was observed upon H1-3
KD alone, addition of ATRA (0.5 μM and 1 μM) in-
duced a significant increase in CD11b expression, with a
marked increase at 0.5 μM (22.6 ± 2.5% vs. 41 ± 4.3%;
P = .008) (Fig. 6c and Additional file 2: Figure S7a and
S7b) and a significant increase in the proportion of the
double positive CD11b/CD11c population (29.8 ± 1.3%
vs. 42.5 ± 2.1%; P = .003) (Fig. 6d). In addition, morpho-
logical and quantification analyses showed that cytoplas-
mic granules, which reflect the beginning of a
maturation process appeared upon H1-3 KD after 96 h
of ATRA-treatment (0.5 μM), (Fig. 6e, f and Additional
file 2: Figure S8). Finally, mRNA expression levels of two
ATRA-induced genes, CYBB and ITGAM, were tested in
H1-3 KD condition under ATRA-treatment; H1-3
downregulation increased the amplitude of ATRA-
induced upregulation of these two genes (Fig. 6g). To
test whether this ATRA-sensitization was dependent of
the presence of NPM1mut or DNMT3AR882C, we per-
formed H1-3 KD in the NPM1wt and DNMT3Awt mye-
loid U937 cell line. Interestingly, H1-3 KD increased the
proportion of the double positive CD11b/CD11c in
0.1 μM ATRA-treated U937 cells and induced morpho-
logical changes (Fig. 6h). Altogether, these results sug-
gest that downregulation of histone H1-3 induces
ATRA-sensitization independently of NPM1 and
DNMT3A mutations.
Discussion
Aberrant epigenetic patterns in leukemia have been de-
scribed but determination of their importance in
leukemia onset and progression is still lacking [22]. We
have studied here the clinical and biological conse-
quences of an epigenetic alteration of the HIST1 locus,
the H3K27me3 HIST1 signature, which we previously
described in CN-AML [10]. We first confirmed the pres-
ence of H3K27me3 HIST1high on 55% of CN-AML and
75% of NPM1mut CN-AML in an independent CN-
AML cohort. H3K27me3 HIST1high impacts on the
survival of CN-AML and NPM1mut CN-AML patients,
and confers a better survival independently of other mo-
lecular markers. While H3K27me3 HIST1high is not as-
sociated with FLT3ITD or DNMT3A mutations,
Fig. 5 H1-3 protein expression is lower in H3K27me3 HIST1high patients. a Abundance of histone H1 subtypes. Results of each H1 subtype are
expressed in iBAQ (Log2) adjusted on the median of the total protein extracted and normalized to total histone amount by patients. Statistical
significance was estimated using unpaired t test, (*) p < 0.05. NS non significant. b Immunoblots of H3, H1, and H1-3 on patient chromatin bound
extracts. The arrow points to the specific band for H1-3. Ratio of H1-3/total-H1 is calculated using Mean Signal Intensity on imageJ software
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Fig. 6 (See legend on next page.)
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IDH2R140Q is overrepresented in H3K27me3 HIST1high
patients (28% vs 7.6%); this is consistent with data
highlighting the functional relationship between
IDH2R140Q mutant expression and histone hyperme-
thylation [23]. Although we do not know the mecha-
nisms underlying the H3K27me3 HIST1high signature,
this focal high level of H3K27me3 may reflect a main-
tained activity of EZH2 previously shown to be associ-
ated with favorable outcome in AML [24]. Our data
provide the first evidence that detecting an aberrant epi-
genetic pattern in addition to gene mutations has clinical
interest and could guide therapeutic choices.
Detection of our epigenetic biomarker in AML dem-
onstrates that H3K27me3 HIST1high status is invariably
associated with a favorable outcome and may reveal a
less aggressive disease. The less aggressive form of AML
associated with H3K27me3 HIST1high is supported by its
anti-correlated stem cell signature, shown to be associ-
ated with an adverse prognosis [19]. It is also supported
by its inflammatory and immune function signature,
which has been associated with a better clinical response
to dexamethasone in NPM1 CN-AML [25]. However, al-
though CD34low AMLs, characterized by a leukemic
stem cell arrested at a precursor-like stage [26], are
enriched in the H3K27me3 HIST1high group, we could
not find H3K27me3 HIST1high exclusively on CD34low
blasts. This suggests that H3K27me3 HIST1high marks a
more mature leukemia independently of the level of
CD34 expression.
The main consequence of the H3K27me3 accumula-
tion at the HIST1 locus may be the downregulation of
the histone genes affected by the repressive epigenetic
mark. Levels of replication-dependent histone gene ex-
pression may reflect aggressiveness of the disease and
may have a survival impact. Indeed, the major histone
gene cluster has been described as one of the most
upregulated across breast cancer progression [9]. Our
study highlighted a peculiar pattern of a lower histone
gene expression and defined a three-HIST1 mRNA sig-
nature, containing three histone genes (HIST1H1D,
HIST1H2BH, and HIST1H2BG) that are directly affected
by the H3K27me3 enrichment and can predict survival
on CN-AML patients. Interestingly, one of the most af-
fected histone genes in our AML data encodes the his-
tone linker H1-3. High level of H1.3 has been previously
linked to cancer aggressiveness, as its overexpression is
associated with malignant ovarian adenocarcinoma [27]
and with a poor pancreatic ductal adenocarcinoma sur-
vival [28]. Given its tight link with differentiation block-
age in cancer cells [29] and given that H1 subtype
individual KDs induce changes, notably in genes in-
volved in cell cycle and chromatin regulation [30], dim-
inution of H1.3 level appears to be a valid effector of the
less aggressive H3K27me3 HIST1high AML phenotype. If
histone linker H1 subtypes have a well-described redun-
dant roles in maintaining nucleosome architecture and
regulating transcription [31], it becomes evident that H1
subtypes have also subtype-specific functions reflected
by selective genomic binding and regulation of chroma-
tin organization [20, 32]. H1 subtypes would influence
chromatin compaction at definite loci affecting specific
gene expression in a tissue specific manner. Thus, it is
tempting to speculate that in our H3K27me3 HIST1high
model, low H1-3 level would influence the differenti-
ation state of the cells due to a specific change in
chromatin targeting. In our cellular models, KD of H1-3
does not induce differentiation but sensitizes the cells to
ATRA-treatment. Interestingly, this sensitivity is inde-
pendent of DNMT3A activity, as the two cell line models
(OCI-AML3 DNMT3Amut and U937 DNMT3Awt) are
both sensitive to ATRA-treatment after H1-3 KD. In the
light of previous reports, which documented an interaction
between H1 proteins and DNMT3B [33, 34], one possibility
is that DNMT3B, although not found mutated in AML,
(See figure on previous page.)
Fig. 6 H1-3 KD promotes granulocytic differentiation in ATRA-treated AML cell lines. a qPCR expression analysis of the indicated histone H1
genes in shCtrl and shH1-3 (KD#1) without (Dox-) or with 6-days-induction of doxycycline (Dox+). Data represent three independent Dox
inductions. Results are normalized on HPRT and expressed in fold change (FC) between Dox+ and Dox− conditions. b Immunoblot of H1-3, H1,
and H3 in chromatin-bound extracts from shCtrl and KD#1 upon (+) or not (−) doxycycline (Dox). c, d Cell surface analysis of granulocytic markers
consecutive to H1-3 KD in OCI-AML3 clones. c Percentage of CD11b positive cells in shCtrl and KD#1 upon doxycycline induction (Dox+) or not
(Dox−) without ATRA (wo ATRA) or with 72 h of ATRA-treatment (0.5 μM or 1 μM). d Percentage of CD11b-CD11c cells upon 72 h of ATRA-
treatment (0.5 μM). Data represent three independent experiments. Statistical significance was estimated using Mann Whitney test *p < 0.05;
**p < 0.005. NS non-significant. e, f Cytological analysis of shCtrl and KD#1 clones upon doxycycline and after 96 h of ATRA treatment (0.5 μM). e
May–Grünwald Giemsa coloration. Black arrows are pointing cytoplasmic azurophilic granules. f Quantification of cells with cytoplasmic granules.
Results are presented as a percentage of positive cells (more than two granules). Statistical significance was estimated using Mann–Whitney test
*p < 0.05; **p < 0.005. g Expression analysis of CYBB and ITGAM in untreated OCI-AML3 and in ATRA-treated (1 μM) KD#1 without or with
doxycycline induction. Gene expression was normalized to two housekeeping genes (PGK1 and PPIA). Data represent three independent
experiments. Statistical significance was estimated using T-test (one-tailed p value). h U937 cells were stably infected by a doxycycline inducible
shCtrl (U-shCtrl) or shH1-3 (U-KD#1 and U-KD#2). Left panel: percentage of CD11b-CD11c cells upon 72 h of ATRA-treatment (0.1 μM). Level of
H1d in the different conditions was measured by immunoblot. Right panel: May–Grünwald Giemsa staining of KD#1 clone with or without
doxycycline upon 72 h hours of ATRA-treatment. Data represent two independent experiments. Statistical significance was estimated using
unpaired Two-tailed t test * p < 0.05; ***p < 0.001
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may be an influential epigenetic partner in AML and in
ATRA sensitivity together with H1-3.
ATRA is successfully used for the treatment of acute
promyelocytic leukemia (APL) by inducing terminal
granulocytic differentiation of APL blasts [35]. To a
lesser extent, ATRA can also induce differentiation in
non-APL cells, in particular in AML with IDH1/IDH2
mutations [36] or induce cell death in NPM1mut AML
when used in combination with Arsenic trioxide [37],
[38]. Interestingly, ATRA sensitization of non-APL cells
has been induced by targeting epigenetic enzymes: inhib-
ition of histone deacetylase (HDAC) with valproic acid
[39] or inhibition of the histone demethylase LSD1/
KDM1A [40] or by targeting SUMOylation [41]. In the
same line, our study suggests that epigenetic modifica-
tions induced by H1-3 targeting could prime AML cells
toward differentiation, revealed by ATRA-sensitivity,
which may explains the more mature phenotype found
in H3K27me3 HIST1high leukemia and suggests that
ATRA could be an efficient differentiating agent in AML
with low H1-3 expression.
Conclusions
We showed that epigenetic silencing of a part of the
HIST1 locus by the H3K27me3 mark is associated with a
better outcome and a mature gene expression profile in
NPM1mut CN-AML and we observed an important role
of histone linker H1-3 expression in AML blast cell dif-
ferentiation. Our study pinpoints the H3K27me3 HIST1
mark and HIST1H1D gene as two biomarkers potentially
useful to stratify patient prognosis and defines targets
that can be considered when developing epidrugs.
Methods
Patient samples
Blast cells were separated from blood or marrow sam-
ples through density-gradient (ficoll) separation, and
stored in liquid nitrogen. Cryopreserved samples, with at
least 70% of blasts, were collected from AML samples
stored at Institut Paoli-Calmettes (IPC) Tumor Bank or
at the Groupe Ouest Est d’Etude des Leucémies Aiguës
et autres Maladies du Sang repository (GOELAMSTHE-
QUE). GOELAMS samples were extracted from multi-
center clinical trials LAM2006IR (NCT00860639) or
LAM2007SA (NCT00590837). All patients received con-
ventional induction chemotherapy consisting in daunor-
ubicine (DNR) and aracytine (ARAC) with or without
Mylotarg in the LAM2006IR trial for patients < 60 years
[42] and idarubicine (IDA) and ARAC with or without
lomustine in the LAM2007SA trial for patients ≥ 60 years
[43]. Informed consent was provided by all patients ac-
cording to the Declaration of Helsinki and subjected to
ethical institutional review board approval.
ChIP-qPCR
Chromatin immunoprecipitation (ChIP) was performed
as previously described [10]. Briefly, frozen samples were
thawed, washed twice in phosphate-buffered saline
(PBS), and chromatin was extracted with TRIS buffer
pH 8, 0.25% Triton. Samples were sonicated to obtain
DNA fragments of 300–600 base pair (Bioruptor PICO)
and chromatin was immunoprecipated with an anti-
H3K27me3 antibody (Abcam #6002). After immunopre-
cipitation, DNA was purified with the I-Pure kit (Diage-
node). Quantification of ChIPed DNA was performed by
real-time PCR using the SsoADV Univer SYBR Green
Supermix (Bio-Rad) and detected with a CFX96 Real-
Time PCR Detection System (Bio-Rad). IgG control
“cycle over the threshold” Ct values were subtracted to
input or IP Ct values and converted into bound value by
2(−(IP Ct or input Ct- IgG IP Ct)). Data are expressed as per-
cent of bound/input. For each HIST1 region, H3K27me3
ChIP signal was double normalized with ChIP signal ob-
tained at a genomic location invariably enriched with
H3K27me3 (HOXD4) and a genomic region depleted of
H3K27me3 (GAPDH). Heatmaps were performed with
gene-e software (Broad institute). Hierarchical clustering
was done using Euclidian distance.
Histone gene nomenclature
The large HIST1 gene cluster on human chromosome
region 6p22 is 2.1 Mb which contains 55 histone genes.
Five genes (HIST1H1A-E) encode the canonical somatic
histone linkers H1 (H1-1, H1-5, H1-2, H1-3, H1-4 re-
spectively) while sets of 10–20 genes encode each of the
core histone proteins (H2A, H2B, H3, and H4). Each of
these genes is translated into a unique mRNA with dis-
tinct 5′ and 3′ extremities, as well as slight nucleotide
changes in the coding region.
RT-qPCR analysis
Total RNA was isolated from patient samples using the
RNeasy mini Kit (Qiagen). RNA was treated with
RNase-free DNase set (Qiagen) to remove contaminating
genomic DNA. The cDNA was synthesized using the
Transcriptor High Fidelity cDNA Synthesis Kit (Roche
Applied Science), quantified by Power SYBR Green
(Roche Applied Science) or TaqMan qPCR. For SYBR
green analyses, signals were detected with a CFX96
Real-Time PCR Detection System (Bio-Rad). Primers
used for gene amplification were designed using Primer3
software and are listed in the table below. Relative ex-
pression levels were determined by the delta Ct method
and expression level of HPRT was used for
normalization. For TaqMan method, PCR Master Mix
(Thermo Fisher) was used and signal detected with 7500
Fast Real-Time PCR System (Applied Biosystem).
Probes used for TaqMan analyses were HIST1H1D:
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Hs00271187_s1; HIST1H2BG: Hs00374317_s1; HIST1
H2BH: Hs00374322_s1; PGK1: Hs00943178_g1; PPIA:
Hs04194521_s1 (Thermo Fisher). Relative expression
levels were determined by the delta Ct method, taking
the mean expression level of PKG1 and PPIA for
normalization [44].
Gene expression profiling
RNA expression profiling of NPM1mut CN-AML was
done with Affymetrix Human gene ST 2.0 and Human
Genome U133 Plus 2.0 DNA microarrays (see Supple-
mental data). Microarray data are accessible under the
accession number E-MTAB-6997.
Protein analysis
Cellular fractionation was done with the subcellular pro-
tein fractionation kit (Thermofisher). Mass spectrometry
procedures are explained in supplemental data. Immu-
noblots were done as previously described [45]. Anti-
bodies used were anti-Histone H1.3 (Abcam, ab24174,
1/750), anti-H1 (Active Motif, #39707, 1/2000), and
anti-H3 (Active Motif, #39163, 1/10000).
Flow cytometry
Flow cytometry analyses were done using a BD-LSRII
cytometer and analyzed using BD-DIVA Version 6.1.2
software (BD Biosciences). Antibodies used were
CD11B-PE (Mac-1), 3:100, Beckman Coulter; CD11B-
APC (M1/70), 1:500, eBioscience; CD11C-PeCy7 (BU-
15), 3:100, Beckman Coulter; DRAQ7™, 1:400; Biostatus,
CD34-PeCy7 (#343516) 1:33, Biolegend.
Cell culture, shRNA lentiviral infection, stable H1-3
knockdown, and treatments
The OCI-AML3 and U937 cells were grown in minimum
essential medium alpha (MEMα) supplemented with 20%
fetal bovine serum or Roswell Park Memorial Institute
(RPMI) medium supplemented with 10% fetal bovine
serum respectively. H1-3 knockdown (KD) was achieved
using doxycycline-induced Dharmacon™SMARTvector™
short hairpin RNA (V3SH7669-229784413, shRNA-1 and
V3SH7669-228676834, shRNA-2). A non-silencing shRNA
(piSMART VSC10730) was used as a control (shCtrl). Cells
containing the SMARTvector™ were sorted using an ARIAIII
cytometer based on red fluorescent protein (RFP) expression
and selected on puromycin (2 μg/mL). KD of H1-3 was ob-
tained by the addition of doxycycline (2 μg/mL) during 5–
7 days. All-trans-retinoic acid (ATRA; Sigma) was dissolved
in dimethylsulfoxyde (DMSO) at 10 mM.
Statistical analyses
Statistical analyses were done using R software (ver-
sion 2.15.2) (The Comprehensive R Archive Network.
http://www.cran.r-project.org/) and Graph Pad Prism
(Graph Pad Software, San Diego, CA, USA) and the
significance of the differences between groups was de-
termined via unpaired T test, Mann–Whitney test, or
exact Fisher test. Data were presented as the me-
dian ± SEM. Overall survival (OS) and event-free sur-
vival (EFS) were calculated from the date of diagnosis
to the date of death or to the date of relapse, death
or the time to no response to intensive induction, re-
spectively. Follow-up was measured from the date of
diagnosis to the date of last news for living patients.
Survivals were calculated using the Kaplan–Meier
method and were compared with the log-rank test.
Uni- and multivariate survival analyses were done
using Cox regression analysis (Wald test). Variables
with a p value < 0.05 were tested in multivariate ana-
lysis. All statistical tests were two-sided at the 5%
level of significance, except when indicated otherwise.
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